Despite the reductions in inflammatory reactions and global myocardial ischaemia associated with off-pump coronary artery bypass grafting (OPCAB) by the avoidance of cardiopulmonary bypass and aortic cross-clamping, 1 brief periods of myocardial ischaemia can result from haemodynamic deterioration and temporary occlusion of the coronary arteries during coronary anastomosis. These brief periods of myocardial ischaemia and subsequent reperfusion can produce some degree of myocardial injury, which may not only affect the individual target areas, but also cause cumulative global myocardial dysfunction after sequential coronary occlusions during multiple grafting. 2 During myocardial ischaemia, intracellular acidosis caused by anaerobic metabolism can lead to cytosolic sodium overload. 2 Cytosolic sodium accumulation can cause cytosolic calcium overload via Na + /Ca 2+ exchange, which leads to mitochondrial calcium overload aggravating cell injury by disrupting mitochondrial function. 3 4 The production of reactive oxygen species (ROS) is also increased after the onset of ischaemia. 2 Reperfusion also results in intracellular calcium overload, generation of ROS, and inflammatory responses, further aggravating myocardial injury. 5 Therefore, strategies that modify these steps can protect the myocardium from ischemic and reperfusion injuries and consequently may enhance patient short-and long-term outcomes after OPCAB. 6 7 Lidocaine is a widely used local anaesthetic and antiarrhythmic agent that has been shown to have cardioprotective effects against myocardial ischaemia and reperfusion injury by blocking cardiac sodium channels, reducing intracellular calcium loading, reducing ROS production, and modulating mitochondrial bioenergetics. 3 4 8 A variety of investigations using experimental animals have shown that systemic lidocaine has a protective effect against myocardial ischaemia and reperfusion injuries.
variables. Inflammatory marker and postoperative major adverse events were also determined.
Methods
The study protocol was approved by the Institutional Review Board and the study was registered at http://cris.cdc.go.kr (KCT0000012). After obtaining written informed consent from each patient, patients aged 18 -80 yr undergoing elective OPCAB under general anaesthesia were enrolled in this prospective, randomized, double-blinded study. Exclusion criteria were contraindications to lidocaine or opioid use, pulmonary or hepatic diseases, psychiatric disorders, recent (within 14 days) myocardial infarction, unstable angina with elevated CK-MB or TnI, elevated serum creatinine (.115 mmol litre 21 ) before surgery, left ventricular ejection fraction (LVEF) ,50%, and patients undergoing emergency or repeat operations, or concomitant valvular or aortic surgery. The study was discontinued in patients who were converted to cardiopulmonary bypass. The primary outcome was a reduction in TnI and CK-MB concentrations at 24 h after operation. Total serum TnI and CK-MB release over the whole 72 h postoperative period was a secondary outcome. Total TnI and CK-MB released, expressed as the area under the curve (AUC) over the 72 h period after surgery, were calculated as described previously.
14 Data were collected on concentrations of C-reactive protein (CRP) as an inflammatory biological marker, intraoperative haemodynamics, the incidence of atrial fibrillation or other arrhythmias after surgery, and postoperative major adverse events including death during hospital stay.
Patients were randomly allocated to two groups based on computer-generated codes that were maintained in sequentially numbered opaque envelopes. On the morning of surgery and before induction of anaesthesia, the allocation envelope was opened by a nurse or anaesthetist with no involvement in patient management, who then prepared either 2% lidocaine or saline in coded 50 ml syringes. After induction of anaesthesia, patients assigned to receive lidocaine were given an i.v. bolus injection of 1. All surgical procedures were performed by two cardiac surgeons (C.-H.C. and S.J. Choo) who were highly experienced in OPCAB surgery and were blinded to the treatment allocation. Median sternotomy was performed in all patients. Whenever possible, the left internal thoracic artery was preferentially used to graft the left anterior descending artery and an intracoronary shunt was inserted into the coronary artery for each anastomosis. After surgery, all patients were transferred to the intensive care unit (ICU). Patients were discharged from the ICU to the general ward when stable and not requiring further ICU monitoring and care.
Serum concentrations of the cardiac enzymes CK-MB and TnI were measured before operation, upon arrival at the ICU and 6, 24, 48, and 72 h after surgery using an ADVIA Centaur CP System w (Siemens, Deerfield, IL, USA), based on a direct chemiluminescence method. Reference ranges for TnI and CK-MB were ,1.5 and 5 ng ml 21 , respectively. CRP was also measured at the same time points. Plasma lidocaine concentrations were determined immediately before harvesting of the graft vessel, at the end of surgery, and 120 min after the surgery using the COBAS INTEGRA 800 analyzer w (Roche Diagnostics, Indianapolis, IN, USA).
Intraoperative haemodynamic variables and effect-site concentrations of propofol and remifentanil were measured 20 min after induction of anaesthesia, immediately before harvesting of the graft vessel, 15 min after the beginning of graft anastomosis, 15 min after the completion of anastomoses, and at the end of surgery. The cumulative doses of propofol and remifentanil during anaesthesia were also calculated. The amount of phenylephrine used, the number of patients requiring inotropes such as dopamine or norepinephrine, the amount of transfused blood, and the amount of fluid infused during surgery were also recorded. We recorded time to extubation from the end of surgery, number of inotropes used and duration of inotropic support, maximal cardiovascular component of the sequential organ failure assessment (SOFAc) score, length of ICU and hospital stay, postoperative adverse events, and death from any cause within 30 days of surgery. The maximum SOFAc score within the first 24 h after surgery was recorded as was the time spent on vasopressive support. 15 Postoperative adverse events included new-onset atrial fibrillation or other arrhythmias, and postoperative myocardial infarction. Postoperative adverse events included new-onset atrial fibrillation or other arrhythmias, and postoperative myocardial infarction. 16 Atrial fibrillation and other arrhythmias were defined as new-onset abnormal rhythms requiring treatment and sustained for more than 15 min. None of the anaesthetists involved in patient management or data collection was aware of the group assignment. All values are expressed as mean (SD), median (range), or number (%). A sample size of 106 patients was estimated from a power analysis from 20 preliminary patients, with a mean (SD) difference in serum TnI concentration at 24 h of 1.98 (2.95) ng ml 21 , showing that a sample size of 48 patients per group would be adequate with a power of 90% at a significance level of 0.05 (two-tailed). To allow for 10% loss during the study period, we intended to recruit a total of 106 patients. Data from this preliminary study were not included in the final analysis. All analyses were performed on an intention-to-treat basis. Between-group comparisons were assessed using the unpaired Student 
Results
From October 1, 2008, to August 30, 2009, a total of 184 patients undergoing elective OPCAB were screened for eligibility, with 109 patients consenting to participate in the study and randomized to intervention or control (Fig. 1) .
Ten of these patients were excluded after enrolment and not included in data analyses, nine due to changes in surgical schedules, and one due to a change in procedure (conversion to cardiopulmonary bypass due to intramyocardial vessels). Thus, 49 patients receiving lidocaine and 50 patients receiving saline were evaluated. The characteristics of the two patient groups were similar ( Table 1 ). There were no significant between-group differences in intraoperative patient data, except for the total dose of remifentanil administered during anaesthesia (Table 2) , which was significantly lower in the lidocaine than in the control group (6944.1 vs 7899.9 mg, P¼0.01). Intraoperative haemodynamic variables were similar in the two groups, as were the incidence of intraoperative atrial fibrillation, other arrhythmias requiring treatment, and the amount of phenylephrine used. Thirteen patients in the lidocaine group required inotropic support with dopamine (n¼7; 3-10 mg kg 21 min 21 )
or norepinephrine (n¼6; 0.05 -0.1 mg kg 21 min 21 ), especially during graft anastomoses, whereas 11 patients in the control group required inotropic support with dopamine (n¼6), norepinephrine (n¼3), or both (n¼1); the difference, however, was not statistically significant ( Table 2 ). The two groups had similar baseline preoperative serum TnI (P¼0.250) and CK-MB (P¼0.742) concentrations. At 24 h after surgery, however, the median serum TnI [0.9 (0.4 -1.8) vs 1.7 (0.9 -3.0) ng ml 21 Postoperative data are reported in Table 3 . The number of patients requiring inotropic agents and also SOFAc scores, time to extubation, duration of ICU stay, and total postoperative hospitalization times were similar in the two groups. The incidence of atrial fibrillation and other arrhythmias after surgery was also similar in the two groups. There were no major complications in either group, including myocardial infarction, need for an intra-aortic balloon pump, and death.
Mean lidocaine plasma concentrations measured in 15 patients were 1.5 (0.3) mg ml 21 immediately before harvesting of the graft vessel, 2.1 (0.3) mg ml 21 at the end of surgery, and 0.6 (0.1) mg ml 21 at 120 min after surgery.
The highest plasma concentrations of lidocaine measured at these time points were 2.0, 2.7, and 0.9 mg ml 21 , respectively. All patients started on lidocaine completed their full course of drug and did not experience any adverse events related to the local anaesthetic, such as severe bradycardia (,40 beats min 21 ), asystole, or neurological symptoms.
Discussion
In this prospective, placebo-controlled, randomized study, a systemic infusion of lidocaine during OPCAB surgery reduced myocardial injury, as shown by significantly lower TnI and CK-MB concentrations 24 h after surgery and 42% and 27% reductions in total serum TnI and CK-MB, respectively, released over 72 h after operation. However, lidocaine had no significant effects on inflammatory markers and had no beneficial effects on short-term postoperative outcomes.
A growing body of literature suggests that lidocaine has protective properties against myocardial ischaemia and reperfusion injury in an isolated animal heart 3 4 9 and in vivo. 10 11 13 17 The cardioprotective effects of lidocaine in animal and experimental studies have included a reduction in ventricular arrhythmias, 17 18 the amelioration of myocardial dysfunction, 3 9 the reduction in high-energy phosphate waste, 8 11 19 and the reduction in infarct size 10 13 18 and 20 In addition, the inclusion of lidocaine in cardioplegic solution was associated with an improved haemodynamic profile during surgery and significantly reduced the serum concentrations of TnI in paediatric patients undergoing cardiac surgery. 21 Our findings are consistent with these previous results. Intracellular sodium and calcium overload, the generation of ROS, and inflammatory responses are important pathophysiological mechanisms responsible for cell injury during myocardial ischaemia and reperfusion. 2 3 8 22 The blockade of sodium channels by lidocaine can reduce intracellular sodium accumulation during ischaemia and reperfusion, which leads to the preservation of adenosine triphosphate due to reductions in the activity of Na + /K + -ATPase and the prevention of Na + -induced intracellular calcium overload. 3 8 Lidocaine has been found to preserve mitochondrial bioenergetics, reduce mitochondrial calcium loading during reperfusion, and reduce the generation of ROS during both ischaemia and reperfusion. 4 23 Lidocaine has been reported to have anti-inflammatory properties, including the inhibition of leucocyte adhesion 24 25 and the reduction of proinflammatory cytokine release, 25 which may be associated with cardioprotection against ischaemia and reperfusion injury. 2 22 All of these effects of lidocaine may contribute to our finding that lidocaine reduced myocardial injury against ischaemia and reperfusion injury in patients undergoing OPCAB. We found that lidocaine did not exert significant effects on postoperative inflammatory responses, a finding consistent with those reported previously, 26 showing that perioperative i.v. infusion of lidocaine had no effect on intraoperative and postoperative inflammatory responses, including CRP and leucocyte count. Thus, inhibition of inflammatory responses may require a more profound sympathetic blockade such as that induced by epidural anaesthesia. 27 28 Our finding suggests that reduction in myocardial damage can be achieved without the blockade of inflammatory responses. We found that i.v. infusion of lidocaine decreased the amount of remifentanil required to maintain haemodynamic stability during surgery. This finding is in agreement with the results of previous studies, 29 30 which showed that i.v. infusion of lidocaine reduced intraoperative opioid consumption. This may have resulted from lidocaine-induced direct cardiovascular depression or sympathetic blockade, or a direct analgesic effect of lidocaine. However, it is unlikely that cardiovascular depression and sympathetic nerve blockade are the primary mechanisms underlying the opioid-sparing effects of i.v. lidocaine because these effects may occur only at higher lidocaine concentrations (50-100 mM) than used here (,10 mM). 31 32 This study had several limitations. The study was not powered to detect statistical differences in clinical outcomes such as ICU or hospital stay. The dose of lidocaine we used was in the established range for the treatment of ventricular arrhythmias, and for analgesic or anti-inflammatory effects with minimal toxicity. 26 29 30 33 Plasma lidocaine concentrations were less than toxic levels in the present study. However, lidocaine concentrations may be higher in patients with depressed cardiac output who commonly undergo cardiac surgery. 33 Indeed, supratherapeutic concentrations of lidocaine may be cardiotoxic rather than cardioprotective. 13 34 Because we enrolled only low-risk patients with preserved LVEF, care should be taken when extrapolating our results from other clinical situations that result in decreased cardiac output, and further studies will be needed to assess optimal lidocaine dosing regimens in these settings.
In conclusion, we found that a continuous i.v. infusion of lidocaine reduced myocardial injury in low-risk patients undergoing elective OPCAB. Larger clinical studies are needed to determine whether the beneficial effects of lidocaine on the myocardium have an impact on clinical outcomes in patients undergoing OPCAB.
